CEVAC CEVAC BROILER ND K / 5000 doses

Similar documents
ESSENTIAL PROTECTION

TRUSTWORTHY POULTRY CEVAC CORYMUNE RANGE. Unique combination vaccines to protect against Coryza and Salmonella. Supported by CEVAC CORYMUNE 4K

CevaC Mass L THe Ceva Mass solution

Vectormune ND a step towards control of Newcastle Disease

making LT protection safer and easier

Ceva s offer to optimize performance Simpler vaccination and better safety

SCIENTIFIC DISCUSSION

Agencia Española de Medicamentos y Productos Sanitarios C/Campezo 1, Edificio Madrid España (Reference Member State)

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

RECOMBINANT VACCINES Live or Killed

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

Suggestions to prevent / control Respiratory Disease Complex in poultry

Dr.Christophe Cazaban

NEWCASTLE KILLED VACCINES IN BROILERS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

WPSA & WVPA Scientific Conference Roberto Soares, DVM, MAM, ACPV Regional Technical Manager - Poultry Ceva Animal Health APAC Malaysia

General context and objectives of the project. Public private partnership (PPP) in Veterinary Public Health. EVADOC project Bangladesh Jan-June 2015

YOU THINK INFLUENZA IS FATAL? THINK AGAIN.

Evaluation of an effervescent tablet presentation of a live attenuated Newcastle Disease vaccine in laboratory and field conditions

2007 : Became Poultry Corporate Marketing Director. Ceva Sante Animale, France

ANSES. Agence Nationale du Médicament Vétérinaire (National Agency for Veterinary Drugs) (Reference Member State) BP FOUGERES CEDEX FRANCE

Is Newcastle disease still a threat for the poultry industry?

SCIENTIFIC DISCUSSION EMEA/V/C/036. Intervet International B.V., Wim de Körverstraat 35, 5831 AN Boxmeer, The Netherlands. N/a

Director Biology Innovation Strategy Department. Ceva Sante Animale, France

Technical meeting 4-6 December 2013 Beijing

Ceva HAND book of poultry diseases

PRESS RELEASE. Libourne, May 29 th, 2013: The signature of a scientific collaboration protocol about avian influenza vaccines between

Comparative immunogenicity of fowl cholera vaccine in Jinding ducks

investing our GLOBAL RESOURCES FUTURE of in the POULTRY We ll be thereṭm

Optimization for Chick Performance Bangkok, Thailand 12 th March 2013

ENCEFAL-VAC SUMMARY OF PRODUCT CHARACTERISTICS

Rotavec Corona Emulsion for injection for cattle. Introduction. Company name: MSD Animal Health. Address: Walton Manor. Walton. Milton Keynes MK7 7AJ

Press Pack. Ceva launches VECTORMUNE AI, a novel technology vaccine for H5 Avian Influenza protection

«Together we are building a new reference to create value beyond animal health»

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Agencia Española de Medicamentos y Productos Sanitarios C/Campezo 1, Edificio Madrid España (Reference Member State)

Molecular diagnosis of infectious bronchitis: recent developments. Richard Currie

Because of the high quality of its contents and the low volume injected, Lapinject VHD can be used safely from

Research note. Merial S.A.S., 29 avenue Tony Garnier Lyon cedex 07 France 2

Immunity and Poultry Health (3)

Etiology. Paramyxovirus type 1 = Newcastle disease.

OIE Situation Report for Highly Pathogenic Avian Influenza

Poultry Disease Manual Characteristics And

IMMUNOGENICITY OF FORMALDYDE INACTIVATED NEWCASTLE DISEASE VIRUS FIELD ISOLATE IN MATERNAL ANTIBODY FREE CHICKENS

Paul-Ehrlich-Institut DE/V/0022/001/II/023/G Page 1

Vaccines of today and products needed for the short-, intermediate- and longterm. OIE/FAO OFFLU Conference Beijing China December 4-6, 2013

Vaccination to stop transmission

AVIAN ENCEPHALOMYELITIS- FOWL POX-PIGEON POX VACCINE

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

PATHOLOGICAL AND IMMUNOLOGICAL STUDY OF AN IN OVO COMPLEX VACCINE AGAINST INFECTIOUS BURSAL DISEASE

Avian Infectious Bronchitis Vaccine, Inactivated

The FIRST intradermal M Hyo vaccine

Vector Newcastle vaccine usage in Latin America. Luiz Sesti, Technical Services Latin America Ceva, Brazil

SUMMARY OF PRODUCT CHARACTERISTICS

Gumboro Disease: where are we with IBDV epidemiology. J.J. (Sjaak) de Wit, DVM, PhD, dipl ECPVS GD Deventer, The Netherlands

ODXJPVID July 2013

VACCINES FOR VETERINARY USE Vaccina ad usum veterinarium

G. W. WOOD J. C. MUSKETT and D. H. THORNTON MAFF, Central Veterinary Laboratory, New Haw, Weybridge, Surrey, U.K.

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

DURATION OF IMMUNITY OF LIVE VACCINE CEVAC S.

INCLUSION BODY HEPATITIS AND HYDROPERICARDIUM SYNDROME (ADENOVIRUS INFECTIONS)

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

AviagenBrief. Marek s Disease Control in Broiler Breeders

Summary of Product Characteristics

ISSN: (Print) (Online) Journal homepage:

The Review of Newcastle Disease Live Vaccines Application. By: M. Abdoshah

Implications and implementation of dayold chick vaccination

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

OIE Situation Report for Avian Influenza

Limitation of the spread and impact of infectious coryza through the use of a continuous disinfection programme

Vet Caress. VETERINARY CARE SERVICES Vaccines and Vaccination

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Evaluation of Two Vaccination Schemes Using Live Vaccines against Newcastle Disease in Chickens

Beurteilungsbericht zur Veröffentlichung. (gemäß 31 Abs. 2 Tierimpfstoff-Verordnung) Poulvac IB Primer

The development of avian influenza vaccines for emergency use

OIE Situation Report for Highly Pathogenic Avian Influenza

VETERINARY SERVICES POLICY STATEMENT

OIE Situation Report for Highly Pathogenic Avian Influenza

Health Products Regulatory Authority

Written by Dr. Rodrigo A. Espinosa, Aviagen Regional Technical Service Veterinarian for North America and Latin America

by Dr Thijs van Dijk and Anna-Christina Riebau Marketing Poultry Vaccines, Lohmann Animal Health

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) GUIDELINE ON USER SAFETY FOR IMMUNOLOGICAL VETERINARY MEDICINAL PRODUCTS

An outbreak of a respiratory infection of multi-agents occurred in poultry flocks in Tripoli, Libya

ASEAN STANDARDS FOR ANIMAL VACCINES

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Updations on the epidemiological situation of Avian Influenza (AI) in Libya. The 11 th JPC REMESA Algiers, Algeria 24-25November2015

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

OIE Regional Workshop on Enhancing Influenza Viruses National Surveillance Systems, Tokyo, August 2014

Her future looks bright

Updated: 26 August 2010

Transcription:

CEVAC BROILER ND K / 5 doses

CEVAC BROILER ND K Newcastle disease a permanent threat Newcastle Disease is highly contagious and exists in a wide range of forms. It is one of the four major poultry diseases worldwide. It takes its toll in all areas where poultry farming is intensive and spreads practically everywhere. Despite health control programmes and extensive vaccination, Newcastle Disease is enzootic in all continents, and also epizootic in many of the world regions. In epizootic situations, it is recommended to combine a live vaccine with an inactivated one to actively immunise young chicks from 1 day old onwards. To achieve this goal, CEVA SANTE ANIMALE offers the high technology vaccine:. Confirmed outbreaks of velogenic Newcastle Disease in 2-21

n outstanding, efficient and innovative technology Innovative An exceptional balance CEVA SANTE ANIMALE's formulation expertise enables to combine a high antigenic concentration with a small volume (.1ml). Beyond the small volume of the dose and its antigenic concentration, also has exceptional fluidity, making it easy to inject, and is perfectly tolerated at the injection site. VACCINE The Best in its generation VISCOSITY at 5 C and 12 rpm (in mpas) A 48.3 B 51.3 Combined inactivated vaccine 8-11 A et B : competitors Oily phase Aqueous phase Vaccine antigens Conventional inactivated vaccine.1 ml / dose is totally safe 34.2

formulation Effective inactivation process Inactivation is one of the key steps in the inactivated vaccine manufacturing process. The objective is to neutralise or kill the virus by removing its capacity to replicate itself, while maintaining its antigenic characteristics. Binary Ethylene Imine (BEI) has been selected as inactivation agent for the CEVAC K inactivated range. Unlike other inactivation agents such as formaldehyde, BEI neutralises the virus by acting on its nucleic acids without modifying its antigenic structure.** offers the best antigenic quality for a better immune response BEI Inactivation Formaldehyde Destruction of ADN or RNA, but no modification of surface antigens. Denaturation of surface antigens simple to use Intramuscular or subcutaneous is remarkably easy to use both intramuscularly and subcutaneously. It can be administered bothwith automatic injection systems and manual syringes. Manual injection Manual vaccination practices are similar to those employed for the vaccination of future layers or future breeders via the subcutaneous or intramuscular route. Automatic vaccination systems Automatic vaccination systems are in most cases set up in the hatchery, enabling fast, accurate injection of all types of vaccine into 1-day-old chicks. They carry out sub cutaneous or intramuscular injection using interchangeable syringes that cannot be deregulated. **Buonavoglia C et al 1988 Veterinary Research Communications, 12,2-3 : 195-197.

n outstanding, efficient and innovative technology % protection 8 6 5 4 3 2 1 85 Challenge 3 weeks Strenghten your protection from 1 day old onwards 25 offers the best protection in the face of high viral challenge. The combination of injected at one day old, with an attenuated live vaccine, produces protection and antibody levels that are significantly higher than those reached from the use of each vaccine individually. This combined vaccination is especially suitable for epidemiological situations where the risks of infection are high.* 5 Challenge 6 weeks + CEVAC Vitapest L Comparison of protection (%) in a virulent ND challenge to commercial chickens at 3 and 6 weeks given by alone and in combination with CEVAC Vitapest L (Ceva 2). % of protection 8 6 5 4 3 2 1 A B C * Bennejean G, 1978. Avian Pathology, 7 : 15-27. Mean HI titre (log2) 7 6 5 4 3 2 1 1 2 3 4 5 Age (days) + CEVAC Vitapest L Mean ND titres observed after vaccination with alone or in combination with CEVAC Vitapest L in commercial chicks vaccinated at 1 day of age (Ceva 2). 5 1 15 2 25 3 35 4 45 5 55 6 65 75 8 85 guarantees a highly significant, lasting protection and serological response, up to 5 days old, that exceed those of its competitors. % protection 12 11 8 6 5 4 3 2 1 Unvaccinated controls Live vaccine Inactivated vaccine Live + inactivated vaccines Âge (days) Evolution of protection procured by live and inactivated vaccines administered individually or combined, to 1-day-old commercial chicks (Bennejean et al., 1978). Efficacy to withstand any challenge 21 days 28 days 42 days Comparison of the (%) protection procured by and that of 3 competitor vaccines (A, B, C) against virulent challenge at 21, 28 and 42 days in commercial chicks (Ceva 21). Mean HI titre (log2) 7 6 5 4 3 2 1 1 2 3 4 5 6 Âge (days) A B C Average ND antibody rates after vaccination with or 3 competitor vaccines (A, B, C) in commercial chicks (Ceva 21).

Cevac Broiler ND K Vaccination programmes These vaccination programmes are given for information only and should be adapted to the local epidemiological context, the local choices for implementation and according to the other vaccinations that have already been recommended. Age Vaccines Route 1 day old in the hatchery Cevac Broiler ND K + Cevac Vitapest L On farms, Cevac Broiler ND K can be injected from 1 to 7 days old. IM or SC for.1 ml Spray Live vaccines are ideally combined with inactivated vaccines in one-day-olds in the hatchery. In cases where injection cannot be carried out in the hatchery, the recommended age limit is 7 days old. It is important that the inactivated vaccine is administered in the same week as the live one. The other vaccinations against Newcastle Disease using live vaccines remain unchanged. Efficacy to stand any test from one day old Remarkably easy to use Totally safe in young chicks Exceptional antigenic quality COMPOSITION: contains La Sota strain of Newcastle Disease virus in inactivated form, homogenized with oily adjuvant and merthiolate as a preservative. INDICATIONS: is recommended for the vaccination of young chickens, especially dayold chicks, against Newcastle Disease (ND). can be used alone or together with a live ND vaccine. ADMINISTRATION AND DOSAGE: should be injected subcutaneously (under the skin of the neck) or by intramuscular route (thigh muscles) at the dose of.1 ml per bird. GENERAL PRECAUTION: Satisfactory protection can be achieved in healthy birds only. Use sterile injection equipment. Keep the vaccine at room temperature (15 to 25 C) for 3 to 4 hours before use. Shake the bottle well before and during use. Check the accuracy of the syringe to ensure that the correct dose is delivered. Once a bottle has been opened, its content must be used up within 24 hours; otherwise, it should be discarded. WARNING: If the vaccine is accidentally injected to the operator, urgent medical attention is required. STORAGE: between 2 C and 8 C protected from light, do not freeze. PRESENTATION: plastic vials of ml ( doses) and 5 ml (5 doses). CEVAC AVIAN BIOLOGICAL RANGE CEVA SANTE ANIMALE S.A. - La Ballastière - B.P. 126-3351 - Libourne Cedex - France - Tél. 33 ()5 57 55 4 4 - Fax 33 ()5 57 55 41 98 e-mail : contact@ceva.com - www.ceva.com